Exploring Unmet Needs to Optimize Neoadjuvant Therapy in Resectable CRC
Richard Kim, MD, discusses the standard treatment approaches and unmet needs for patients with resectable colorectal cancer.
Related Articles
Brexu-Cel Demonstrates Efficacy, Safety in Older Patients with R/R Mantle Cell Lymphoma
Brexu-cel demonstrated clinical activity and safety in patients over 70 years of age with relapsed/refractory mantle cell lymphoma.
Rina-S Displays Early Efficacy in Advanced Ovarian Cancer
Elizabeth K. Lee, MD, discusses data from the phase 1/2 RAINFOL-01 study of Rina-S in advanced ovarian cancer.
Denosumab Biosimilars Earn Positive CHMP Opinion for Osteoporosis and Cancer-Related Bone Disease
The EMA’s CHMP has issued a positive opinion for the denosumab biosimilars Osvyrti and Jubereq for the same indications as the reference products.
ctDNA-Guided Approaches Reveal Effective Adjuvant Agents in MRD+ CRC
Tanios S. Bekaii-Saab, MD, details studies of ctDNA-guided strategies that are elucidating the role of adjuvant therapies in CRC and agents of promise.
Silmitasertib Drives Disease Control in Advanced Basal Cell Carcinoma
Silmitasertib generated disease control in patients with locally advanced or metastatic basal cell carcinoma.
Revisit Every OncLive On Air Episode From March 2025
Read a recap of the episodes of OncLive On Air that aired in March 2025.
D-VRd Plus Daratumumab/Lenalidomide Maintenance Yields Favorable PFS Outcomes in High-Risk Myeloma
D-VRd with daratumumab/lenalidomide maintenance led to sustained PFS and MRD negativity across high-risk subgroups of newly diagnosed multiple myeloma.
Cilta-Cel Significantly Boosts MRD Negativity Rates in Lenalidomide-Refractory Myeloma
Cilta-cel improved rates of MRD negativity and 30-month PFS vs SOC in patients with lenalidomide-refractory multiple myeloma with MRD negativity.
ctDNA-Guided Approaches Reveal Effective Adjuvant Agents in MRD+ CRC
Tanios S. Bekaii-Saab, MD, details studies of ctDNA-guided strategies that are elucidating the role of adjuvant therapies in CRC and agents of promise.
AACR Annual Meeting
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.